[Form 4] CervoMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) reported insider share purchases by its CEO & President, who is also a director and 10% owner. On 11/17/2025, the reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with actual prices ranging from $8.39 to $8.46. Following this, the reporting person directly beneficially owned 1,484,078 shares.

On the same date, an additional 10,793 shares were purchased at a weighted average price of $8.46 (with prices from $8.38 to $8.50) for the reporting person’s spouse’s IRA, which is reported as indirect ownership of 12,500 shares. The ownership totals also include shares held jointly with the spouse and in a Roth IRA.

Insights

Equity & Governance Analyst

CEO/10% owner of CervoMed increased holdings via open-market stock purchases, a generally positive governance and alignment signal.

The filing shows the CEO, who is also a director and 10% owner of CervoMed Inc. (CRVO), buying common stock in open-market transactions on 11/17/2025. One purchase added 10,807 shares at a weighted average price of $8.46, bringing directly held and jointly held shares (including a Roth IRA) to 1,484,078. A separate open-market purchase of 10,793 shares at a weighted average price of $8.46 increased indirect holdings in the spouse’s IRA to 12,500 shares.

These are discretionary purchases for cash in the public market, not option exercises or grants, and they increase both direct and indirect beneficial ownership. The reporting person and spouse already hold a large block, including 1,471,578 shares held jointly and 12,500 shares in the reporting person’s Roth IRA, which underscores concentrated insider ownership. The prices are reported as weighted averages, with actual trade prices in narrow ranges around $8.39–$8.50, which indicates multiple small fills rather than a single negotiated block trade.

The key practical takeaway is that a senior insider with board representation is committing additional personal capital at these price levels, which often signals confidence in the business, though no motive is stated. The absence of derivative transactions and the focus on common stock purchases simplify the picture of insider exposure and incentives. A useful near-term reference point is the transaction date of 11/17/2025, as future ownership or trading pattern changes in subsequent Form 4s can be compared against this increased base of 1,484,078 direct/joint shares and 12,500 spouse IRA shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALAM JOHN J

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		P		10,807(1)	A	$8.46(2)	1,484,078(3)	D
Common Stock	11/17/2025		P		10,793(1)(4)	A	$8.46(5)	12,500(4)	I	Spouse's IRA(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares purchased in open-market transactions.

2. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.39 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

3. Includes (i) 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors and (ii) 12,500 shares held by the John J. Alam Roth IRA.

4. Shares held by the Sylvie Gregoire Roth IRA.

5. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.38 to $8.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CervoMed (CRVO) report on this Form 4?

The filing reports that CervoMed’s CEO & President, who is also a director and 10% owner, purchased common stock in open‑market transactions on 11/17/2025, both directly and through a spouse’s IRA.

How many CervoMed (CRVO) shares did the insider buy directly?

The reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with prices ranging from $8.39 to $8.46.

How many CervoMed (CRVO) shares were bought through the spouse’s IRA?

The filing shows a purchase of 10,793 shares for the Sylvie Gregoire Roth IRA at a weighted average price of $8.46, with individual trade prices from $8.38 to $8.50.

What is the insider’s CervoMed (CRVO) share ownership after these trades?

After the reported transactions, the insider directly beneficially owned 1,484,078 shares and indirectly owned 12,500 shares through the spouse’s IRA.

How are the insider’s CervoMed (CRVO) holdings structured?

The holdings include 1,471,578 shares held jointly with the reporting person’s spouse, 12,500 shares held by the John J. Alam Roth IRA, and additional shares in the spouse’s Roth IRA.

Were the CervoMed (CRVO) insider purchases open‑market transactions?

Yes. The explanation states that the 10,807 and 10,793 shares were purchased in open‑market transactions at specified price ranges.